AFT Pharmaceuticals Limited Stock

Equities

AFT

NZAFTE0001S4

Pharmaceuticals

End-of-day quote New Zealand S.E. 18:00:00 2024-04-25 EDT 5-day change 1st Jan Change
3.09 NZD +0.65% Intraday chart for AFT Pharmaceuticals Limited -1.59% -11.71%

Financials

Sales 2024 * 193M 114M 156M Sales 2025 * 220M 131M 179M Capitalization 324M 192M 263M
Net income 2024 * 15M 8.91M 12.18M Net income 2025 * 17M 10.09M 13.8M EV / Sales 2024 * 1.83 x
Net Debt 2024 * 28.28M 16.79M 22.96M Net Debt 2025 * 26.88M 15.96M 21.82M EV / Sales 2025 * 1.59 x
P/E ratio 2024 *
21.3 x
P/E ratio 2025 *
18.7 x
Employees 100
Yield 2024 *
0.52%
Yield 2025 *
0.74%
Free-Float 25.53%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.65%
1 week-1.59%
Current month-1.28%
1 month+1.31%
3 months-15.80%
6 months-8.85%
Current year-11.71%
More quotes
1 week
3.06
Extreme 3.06
3.13
1 month
3.05
Extreme 3.05
3.24
Current year
2.84
Extreme 2.84
3.85
1 year
2.84
Extreme 2.84
3.92
3 years
2.84
Extreme 2.84
5.00
5 years
2.09
Extreme 2.09
5.65
10 years
1.70
Extreme 1.7
5.65
More quotes
Managers TitleAgeSince
Founder - 97-09-03
Founder - 97-09-03
Director of Finance/CFO - 97-09-03
Members of the board TitleAgeSince
Director/Board Member 67 20-12-22
Chairman - 15-06-21
Founder - 97-09-03
More insiders
Date Price Change Volume
24-04-26 3.09 +0.65% 31,153
24-04-24 3.07 -1.92% 23,824
24-04-23 3.13 +1.29% 1,862
24-04-22 3.09 -1.59% 373
24-04-19 3.14 +2.61% 2,579

End-of-day quote New Zealand S.E., April 25, 2024

More quotes
AFT Pharmaceuticals Limited is a New Zealand-based multinational pharmaceutical company. The Company develops, markets and distributes a portfolio of pharmaceutical products across a range of therapeutic categories, which are distributed across three pharmaceutical distribution channels: over-the-counter (OTC), prescription and hospital. Its product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. The Company develops and in-licenses products for sale by its own dedicated sales teams in Australia and New Zealand and in certain Southeast Asian markets, and out-licenses its products to local licensees and distributors in the rest of the world. A-Scabies, Allersoothe, Allersoothe Elixir, BecloClear, Bites, Calci-Tab, Candacort, Candacort Minipak, Candaderm, Coco-Scalp, Combolieve, Cromo-Fresh, Dry skin, Eczema, Emulsifying Ointment BP, Fenpaed, Fenpaed Double Strength, Ferro-Sachets, HYLO-FORTE and others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
3.09 NZD
Average target price
3.7 NZD
Spread / Average Target
+19.74%
Consensus

Quarterly revenue - Rate of surprise